Risk stratification based on DNA damage-repair-related signature reflects the microenvironmental feature, metabolic status and therapeutic response of breast cancer

DNA damage-repair machinery participates in maintaining genomic integrity and affects tumorigenesis. Molecular signatures based on DNA damage-repair-related genes (DRGs) capable of comprehensively indicating the prognosis, tumor immunometabolic profile and therapeutic responsiveness of breast cancer (BRCA) patients are still lacking. Integrating public datasets and bioinformatics algorithms, we developed a robust prognostic signature based on 27 DRGs. Multiple patient cohorts identified significant differences in various types of survival between high- and low-risk patients stratified by the signature. The signature correlated well with clinicopathological factors and could serve as an independent prognostic indicator for BRCA patients. Furthermore, low-risk tumors were characterized by more infiltrated CD8+ T cells, follicular helper T cells, M1 macrophages, activated NK cells and resting dendritic cells, and fewer M0 and M2 macrophages. The favorable immune infiltration patterns of low-risk tumors were also accompanied by specific metabolic profiles, decreased DNA replication, and enhanced antitumor immunity. Low-risk patients may respond better to immunotherapy, and experience improved outcomes with conventional chemotherapy or targeted medicine. Real-world immunotherapy and chemotherapy cohorts verified the predictive results. Additionally, four small molecule compounds promising to target high-risk tumors were predicted. In vitro experiments confirmed the high expression of GNPNAT1 and MORF4L2 in BRCA tissues and their association with immune cells, and the knockdown of these two DRGs suppressed the proliferation of human BRCA cells. In summary, this DNA damage-repair-related signature performed well in predicting patient prognosis, immunometabolic profiles and therapeutic sensitivity, hopefully contributing to precision medicine and new target discovery of BRCA.

[1]  Hui Li,et al.  Construction of a DNA damage repair gene signature for predicting prognosis and immune response in breast cancer , 2023, Frontiers in Oncology.

[2]  Juanjuan Tang,et al.  Knockdown of replication protein A 3 induces protective autophagy and enhances cisplatin sensitivity in lung adenocarcinoma by inhibiting AKT/mTOR signaling via binding to cyclin‐dependent kinases regulatory subunit 2 , 2022, Drug development research.

[3]  A. Reda,et al.  Anti-neoplastic action of Cimetidine/Vitamin C on histamine and the PI3K/AKT/mTOR pathway in Ehrlich breast cancer , 2022, Scientific Reports.

[4]  A. Reda,et al.  Anti-neoplastic action of Cimetidine/Vitamin C on histamine and the PI3K/AKT/mTOR pathway in Ehrlich breast cancer , 2022, Scientific Reports.

[5]  Shao-Cong Sun,et al.  Dapl1 controls NFATc2 activation to regulate CD8+ T cell exhaustion and responses in chronic infection and cancer , 2022, Nature Cell Biology.

[6]  Huanming Yang,et al.  CRISPR-mediated MECOM depletion retards tumor growth by reducing cancer stem cell properties in lung squamous cell carcinoma , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Yizhou Jiang,et al.  Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy , 2022, Journal of Hematology & Oncology.

[8]  Yue Zhang,et al.  Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer , 2022, Cell.

[9]  Yizhi Yu,et al.  Development of a metabolism-related signature for predicting prognosis, immune infiltration and immunotherapy response in breast cancer. , 2022, American Journal of Cancer Research.

[10]  Chen Liang,et al.  Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives , 2021, Molecular Cancer.

[11]  E. Yang,et al.  Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer , 2021, Frontiers in Oncology.

[12]  A. Wawruszak,et al.  Vorinostat (SAHA) and Breast Cancer: An Overview , 2021, Cancers.

[13]  A. Turnbull,et al.  A Novel Approach for the Discovery of Biomarkers of Radiotherapy Response in Breast Cancer , 2021, Journal of personalized medicine.

[14]  Yuan Guo,et al.  Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer. , 2021, ACS applied materials & interfaces.

[15]  P. Zhou,et al.  DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy , 2021, Signal Transduction and Targeted Therapy.

[16]  L. Farahmand,et al.  Breast cancer immunotherapy: Current and novel approaches. , 2021, International immunopharmacology.

[17]  Nan Wang,et al.  Screening of DNA Damage Repair Genes Involved in the Prognosis of Triple-Negative Breast Cancer Patients Based on Bioinformatics , 2021, Frontiers in Genetics.

[18]  F. Végran,et al.  Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy , 2021, Journal for ImmunoTherapy of Cancer.

[19]  Pengyu Chen,et al.  A Prognostic DNA Damage Repair Genes Signature and Its Impact on Immune Cell Infiltration in Glioma , 2021, Frontiers in Oncology.

[20]  M. Shan,et al.  DCTPP1, an Oncogene Regulated by miR-378a-3p, Promotes Proliferation of Breast Cancer via DNA Repair Signaling Pathway , 2021, Frontiers in Oncology.

[21]  J. San Román,et al.  Hyaluronic acid (HA)-coated naproxen-nanoparticles selectively target breast cancer stem cells through COX-independent pathways. , 2021, Materials science & engineering. C, Materials for biological applications.

[22]  Shimin Chen,et al.  Identification and external validation of a prognostic signature associated with DNA repair genes in gastric cancer , 2021, Scientific Reports.

[23]  Dingzhi Huang,et al.  Upregulation of GNPNAT1 Predicts Poor Prognosis and Correlates With Immune Infiltration in Lung Adenocarcinoma , 2021, Frontiers in Molecular Biosciences.

[24]  G. Crabtree,et al.  Increased ACTL6A Occupancy Within mSWI/SNF Chromatin Remodelers Drives Human Squamous Cell Carcinoma , 2021, bioRxiv.

[25]  Weidong Wei,et al.  Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer , 2021, Journal of experimental & clinical cancer research : CR.

[26]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[27]  F. Lin,et al.  ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer , 2021, Proceedings of the National Academy of Sciences.

[28]  Caicun Zhou,et al.  Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy , 2021, Acta pharmaceutica Sinica. B.

[29]  Clifford A. Meyer,et al.  In Vivo CRISPR Screens Identify E3 Ligase Cop1 as a Modulator of Macrophage Infiltration and Cancer Immunotherapy Target , 2020, bioRxiv.

[30]  Nadezhda T. Doncheva,et al.  The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..

[31]  Benjamin A. Shoemaker,et al.  PubChem in 2021: new data content and improved web interfaces , 2020, Nucleic Acids Res..

[32]  Dongqiang Zeng,et al.  IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures , 2020, bioRxiv.

[33]  A. Morandi,et al.  Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance. , 2020, Trends in cancer.

[34]  T. Gajewski,et al.  Cancer and the Microbiome: Influence of the commensal microbiota on cancer, immune responses, and immunotherapy. , 2020, Gastroenterology.

[35]  Z. Dai,et al.  Prediction of Overall Survival Among Female Patients With Breast Cancer Using a Prognostic Signature Based on 8 DNA Repair–Related Genes , 2020, JAMA network open.

[36]  M. Moasser,et al.  Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer , 2020, Nature Communications.

[37]  Zemin Zhang,et al.  The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications , 2020, Cellular & Molecular Immunology.

[38]  J. Rathmell,et al.  Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. , 2020, Molecular cell.

[39]  Xia Li,et al.  Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers , 2020, Nature Communications.

[40]  Deepak Kgk,et al.  Tumor Microenvironment: Challenges and Opportunities in Targeting Metastasis of Triple Negative Breast Cancer. , 2020, Pharmacological research.

[41]  Weina Ma,et al.  Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier , 2020, Theranostics.

[42]  C. Sempoux,et al.  S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development , 2020, Gut.

[43]  M. Toi,et al.  DNA damage repair functions and targeted treatment in breast cancer , 2020, Breast Cancer.

[44]  A. Zannetti,et al.  Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer. , 2020, Seminars in cancer biology.

[45]  S. Perez,et al.  The balance between breast cancer and the immune system: challenges for prognosis and clinical benefit from immunotherapies. , 2019, Seminars in cancer biology.

[46]  David L. Marron,et al.  B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer , 2019, Cell.

[47]  H. Clevers,et al.  Inadequate DNA Damage Repair Promotes Mammary Transdifferentiation, Leading to BRCA1 Breast Cancer , 2019, Cell.

[48]  G. Shapiro,et al.  PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. , 2019, Cancer discovery.

[49]  G. Mills,et al.  Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy , 2019, Nature Metabolism.

[50]  Ho-Joon Lee,et al.  Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer , 2018, bioRxiv.

[51]  J. Pollard,et al.  Targeting macrophages: therapeutic approaches in cancer , 2018, Nature Reviews Drug Discovery.

[52]  Xia Li,et al.  TIP: A Web Server for Resolving Tumor Immunophenotype Profiling. , 2018, Cancer research.

[53]  X. Liu,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[54]  S. Loi,et al.  Checkpoint blockade in the treatment of breast cancer: current status and future directions , 2018, British Journal of Cancer.

[55]  Paul Ellis,et al.  Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial , 2018, Nature Medicine.

[56]  P. Kristel,et al.  RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[58]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[59]  H. Aburatani,et al.  JUNB governs a feed-forward network of TGFβ signaling that aggravates breast cancer invasion , 2017, Nucleic acids research.

[60]  Tiara Bunga Mayang Permata,et al.  DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells , 2017, Nature Communications.

[61]  Michael S. Goldberg,et al.  DNA Damage and Repair Biomarkers of Immunotherapy Response. , 2017, Cancer discovery.

[62]  B. Yousefi,et al.  DNA repair and damage pathways in breast cancer development and therapy. , 2017, DNA repair.

[63]  N. Harbeck,et al.  Breast cancer , 2017, The Lancet.

[64]  G. Hortobagyi,et al.  PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.

[65]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[66]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[67]  M. Salto‐Tellez,et al.  Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer , 2016, Journal of the National Cancer Institute.

[68]  Lajos Pusztai,et al.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  D. Gabrilovich,et al.  The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. , 2016, Trends in immunology.

[70]  Yuri A. Mirokhin,et al.  A Description of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Common Data Analysis Pipeline. , 2016, Journal of proteome research.

[71]  S. Severi,et al.  Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[72]  Wei Wang,et al.  TRAF Family Member-associated NF-κB Activator (TANK) Inhibits Genotoxic Nuclear Factor κB Activation by Facilitating Deubiquitinase USP10-dependent Deubiquitination of TRAF6 Ligase* , 2015, The Journal of Biological Chemistry.

[73]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[74]  Paul Geeleher,et al.  pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.

[75]  J. Pollard,et al.  Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer. , 2014, Cancer research.

[76]  F. Climent,et al.  VAV3 mediates resistance to breast cancer endocrine therapy , 2014, Breast Cancer Research.

[77]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[78]  Xiaojing Guo,et al.  Estrogen Receptor α Regulates ATM Expression through miRNAs in Breast Cancer , 2013, Clinical Cancer Research.

[79]  Romain M. Larive,et al.  The Rho Exchange Factors Vav2 and Vav3 Control a Lung Metastasis–Specific Transcriptional Program in Breast Cancer Cells , 2012, Science Signaling.

[80]  N. Wilson,et al.  Distinct regulation of c-myb gene expression by HoxA9, Meis1 and Pbx proteins in normal hematopoietic progenitors and transformed myeloid cells , 2012, Blood Cancer Journal.

[81]  A. Ashworth,et al.  The DNA damage response and cancer therapy , 2012, Nature.

[82]  L. Augenlicht,et al.  Single-cell transcription site activation predicts chemotherapy response in human colorectal tumors. , 2008, Cancer research.

[83]  E. Wagner,et al.  Targeting c-Jun and JunB proteins as potential anticancer cell therapy , 2008, Oncogene.

[84]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[85]  L. Coussens,et al.  Tumor stroma and regulation of cancer development. , 2006, Annual review of pathology.

[86]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[87]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[88]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.